29 results
Thumbnail

D3.17 - Outcomes of Anti-Tuberculosis Drug Reintroduction Following Adverse Drug Reactions among Adult Patients at a Tertiary Hospital in the Philippines (2022-2024)

Thumbnail

D3.27 - Nivolumab-Induced Psoriasiform Eruption: Diagnostic Challenge Between Immune-Related Toxicity and Drug Allergy

Thumbnail

D3.30 - Automated generation of structured clinical databases in drug hypersensitivity: real-world validation in patients with proton pump inhibitor reactions

Thumbnail

D3.16 - Increase of Post–SARS-CoV-2 Rashes Mimicking Penicillin Allergy in Children with Group A beta-hemolytic Streptococcus Infection: an emerging and challenging issue

Thumbnail

D3.18 - Role of an Allergological Work-up in Antibiotic Allergy Delabeling in Mexican Pediatric Patients

Thumbnail

D3.20 - Study of “in vitro” cross reactivity between nsLTP’s comparing “in silico” results with a new specific IgE test based on immunoblot methodology

Thumbnail

D3.21 - When the Patient Diagnoses Herself: Amoxicillin-Induced Acute Pancreatitis as a Rare Manifestation of Drug Hypersensitivity

Thumbnail

D3.25 - Machine learning models to differentiate cross-reactive and selective-hypersensitive patients to nonsteroidal anti-inflammatory drugs hypersensitivity

Thumbnail

D3.31 - Real-world Practices in the Diagnosis and Evaluation of Allergic Rhinitis among Korean Specialists

Thumbnail

D3.28 - Effectiveness of the Hypoallergenic Home Visit Program in Treating Moderate-to-Severe Allergic Rhinitis: An Environmental Control Study in Southern China

Thumbnail

D3.29 - China's First Three-Dimensional Indoor Dust Mite Allergen Distribution Map: A Cross-Sectional Study of Dust Mite-Allergic Patients in Guangzhou

Thumbnail

D3.32 - China's Hypoallergenic Home Visit Program: A Standardized Process for Environmental Control Based on a Mobile Application

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project